Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 67.00K shares, a 25.55% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 15.30K shares, a 108.44% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 8.00K shares, a 87.87% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 4.94K shares, a 88.54% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 73.66K shares, a 81.52% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 398.52K shares, a 68.85% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 236.03K shares, a 49.16% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 158.24K shares, a 39.60% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 67.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 95.25K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 15.30K shares 10-Q · filed 2026-05-14 | 81.62K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 8.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 73.66K shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 4.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 131.62K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 53.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 169.83K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 7.34K shares 10-Q · filed 2025-05-06 | 204.16K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 65.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 398.52K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 43.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 423.82K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 87.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 398.81K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 201.70K shares 10-Q · filed 2024-05-08 | 423.46K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 91.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 236.03K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 18.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 148.38K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 112.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 185.74K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 14.27K shares 10-Q · filed 2023-05-04 | 144.24K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 3.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | 158.24K shares 10-K · filed 2023-03-03 |
| 2022-09-30 | 55.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 212.66K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 70.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 225.19K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 28.27K shares 10-Q · filed 2022-05-05 | 211.61K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 58.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | 261.97K shares 10-K · filed 2022-03-09 |
| 2021-09-30 | 68.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 221.06K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 57.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 180.69K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 78.63K shares 10-Q · filed 2021-05-06 | 147.42K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 17.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 113.47K shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 27.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | |
| 2020-06-30 | 24.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | |
| 2020-03-31 | 44.69K shares 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |